Home
About
Our Science
Osteoarthritis
Cancer
Contact
Home
About
Our Science
Osteoarthritis
Cancer
Contact
More
  • Home
  • About
  • Our Science
  • Osteoarthritis
  • Cancer
  • Contact
  • Home
  • About
  • Our Science
  • Osteoarthritis
  • Cancer
  • Contact

Welcome to VetrixBio

Our Mission

Our Expertise

Our Expertise

We are committed to improving the lives of companion animals by developing innovative biotherapeutics to address cancer and osteoarthritis.

Our Expertise

Our Expertise

Our Expertise

Our team of veterinarians, researchers and business leaders have extensive experience in developing and commercializing cutting-edge therapies in animal and human health. We are constantly exploring new ways to improve patient outcomes.

Our Pipeline

Our Expertise

Our Pipeline

Cancer therapy for animals is at a threshold to leverage immunotherapy advances developed in human health over the last 20 years. We are applying these biologic approaches 

to make cancer care 

more accessible for pets.


Treatment of osteoarthritis has mainly focused on managing the associated pain. We are focused on applying biologic approaches that are disease modifying and have potential for regenerative outcomes in addition to managing pain.

Leadership

Graham Lumsden

As cofounder and CEO of VetrixBio, Graham brings more than 35 years development, commercial and executive experience in both animal and human health. He is a Director of Kibow Therapeutics (kidney disease) and the former CEO of Biomarck Pharmaceuticals (inflammatory and immunological diseases), Motif Bio (antibacterials), and Tiemed LLC (oral delivery). He spent more than twenty years in senior roles at Merck & Co. (animal health, osteoporosis and contraceptives). 


Graham holds a BVM&S from the University of Edinburgh and a Postgraduate Diploma in Marketing from the Chartered Institute of Marketing in the U.K. He also holds the MRCVS qualification.

Peter Hanson

As cofounder, President and CSO of VetrixBio, Peter brings more than 30 years of clinical, development, operational and executive experience in both animal and human health. He is the former COO at eGenesis (gene editing & xenotransplantation) and CDOO at Centrexion Therapeutics (pain). Before that he held senior roles in animal health R&D (Merck, Merial, and Abbott) in the areas of pain, oncology, parasitology and vaccines. 


Peter holds a BA summa cum laude and DVM from the University of Minnesota and a large animal surgery residency certificate, MS and PhD from the University of Wisconsin. He is a Diplomate of the American College of Veterinary Surgeons. 

VetrixBio LLC

Copyright © 2025 VetrixBio LLC - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept